drugset / Trial / NCT01225874
Biomarkers to Classify Young Patients With Acute Lymphoblastic Leukemia (ALL) and Remission Induction Therapy in Young Patients With B-Precursor ALL
Non-randomizedSingle-groupOpen-labelTreatment
Summary
RATIONALE: Studying samples of blood or bone marrow from patients with cancer in the laboratory may help doctors predict how well patients will respond to treatment. Drugs used in chemotherapy work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Giving more than one drug (combination chemotherapy) may kill more cancer cells. PURPOSE: This trial is studying biomarkers to classify young patients with acute lymphoblastic leukemia (ALL) and remission induction therapy in young patients with B-precursor ALL.
Timeline
- Start
- 1999-12
- Primary completion
- 2006-03
- Completion
- —
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Calaspargase Pegol | Protein / enzyme biologic | — | Intramuscular |
| Subject | Cytarabine | Small molecule | — | Intrathecal |
| Subject | Daunorubicin | Small molecule | — | Intravenous |
| Subject | Dexamethasone | Small molecule | — | Oral |
| Subject | Methotrexate | Small molecule | — | Intrathecal |
| Subject | Pegaspargase | Protein / enzyme biologic | — | Intramuscular |
| Subject | Prednisone | Other / unclassified | — | Oral |
| Subject | Vincristine | Small molecule | — | Intravenous |